Web10 Apr 2024 · Background: We aimed to evaluate the prognostic value of imaging biomarkers on 18F-FDG PET/CT in extensive-stage small-cell lung cancer (ES-SCLC) patients undergoing first-line chemo-immunotherapy. Methods: In this multicenter and retrospective study, we considered two cohorts, depending on the type of first-line therapy: chemo … Web13 Jan 2024 · Exploratory biomarker analyses according to PD-L1 expression levels on both tumor cells (TCs) and tumor-infiltrating immune cells (ICs) were conducted in the biomarker-evaluable population (BEP). Prespecified secondary analyses according to bTMB status were conducted in the BEP. Procedures
Recent developments in the treatment of small cell lung cancer
Web18 Jun 2024 · Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers. Despite high rates of response to first-line chemotherapy and radiotherapy, patients with extensive-stage disease eventually relapse, and very few patients survive more than 5 years from diagnosis. Treatment options for recurrent or refractory disease are limited, … Web8 Aug 2024 · Small cell lung cancer (SCLC) is characterized by morphologic, epigenetic and transcriptomic heterogeneity. Subtypes based upon predominant transcription factor … depakine chrono djelovanje
A Highly Efficient Gene Expression Programming (GEP) Model for …
WebBlood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean variant allele frequency (VAF) and radiographic total-body tumor volume (TV) in patients with SCLC. We identified matched … Web27 Mar 2024 · Define biomarker in SCLC. Date 27 Mar 2024. Session What’s next in the management of SCLC? Topics Tumour Site Small Cell Lung Cancer . Presenters Martin Frueh. Authors M. Frueh. Author affiliations. Kantonsspital St. Gallen, St. Gallen/CH ... Web1 Oct 2024 · Novel SCLC biomarkers are urgently required to improve current diagnostic and treatment modalities. MYCN encodes the proto-oncogene N-Myc that is overexpressed in SCLC, but its downstream effectors are poorly characterized. Here, we investigated the role of the N-Myc/Skp2/p27 axis during SCLC progression. dep su uova